Skip to main content
logo
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.800
+0.120 (3.26%)
At close: May 6, 2026, 4:00 PM EDT
4.010
+0.210 (5.53%)
Pre-market: May 7, 2026, 5:48 AM EDT

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Cap
267178356330340
Market Cap Growth
1916.22%405.79%-44.53%113.51%-91.25%-
Enterprise Value
176.4186.4718.5812.0119.99301.74
Last Close Price
3.803.743.796.885.9078.10
PE Ratio
--4.73-1.03-0.90-1.37-12.40
PS Ratio
--26.6228.351.245.58
PB Ratio
1.191.181.361.110.96-
P/TBV Ratio
1.571.511.350.660.83-
P/FCF Ratio
--3.90-1.02-2.51-1.16-37.92
P/OCF Ratio
--3.98-1.03-2.53-1.27170.94
EV/Sales Ratio
--14.055.360.844.96
EV/EBITDA Ratio
--1.88-0.49-0.35-0.78-25.70
EV/EBIT Ratio
--1.77-0.43-0.32-0.69-22.53
EV/FCF Ratio
--1.89-0.54-0.47-0.78-33.69
Debt / Equity Ratio
0.030.030.160.090.17-
Debt / EBITDA Ratio
-0.13-0.13-0.12-0.17-0.23-0.40
Debt / FCF Ratio
-0.13-0.13-0.13-0.23-0.23-0.53
Net Debt / Equity Ratio
-0.60-0.60-0.62-0.88-0.29-
Net Debt / EBITDA Ratio
1.981.980.421.480.362.96
Net Debt / FCF Ratio
1.981.980.472.000.363.88
Asset Turnover
-00.020.030.360.88
Quick Ratio
9.139.132.615.231.371.80
Current Ratio
9.469.462.985.451.471.90
Return on Equity (ROE)
14.96%14.96%-81.92%-95.51%-120.35%-
Return on Assets (ROA)
-45.12%-45.12%-66.98%-56.47%-43.74%-19.46%
Return on Invested Capital (ROIC)
-118.31%-118.31%-238.36%-181.32%-123.04%-45.15%
Return on Capital Employed (ROCE)
-49.36%-49.36%-78.49%-69.84%-63.84%-26.74%
Earnings Yield
1.60%-21.12%-97.10%-111.05%-73.06%-8.07%
FCF Yield
-17.12%-25.67%-98.37%-39.89%-86.20%-2.64%
Buyback Yield / Dilution
-562.28%-562.28%-67.74%-26.86%-59.20%-1.21%
Total Shareholder Return
-562.28%-562.28%-67.74%-26.86%-59.20%-1.21%
Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q